Skip to main content

Table 3 Safety endpoints

From: Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial

Variable Control arm CVVHDF, n = 33 Intervention arm CVVHD-HCO, n = 35 p value
Clinical outcome    
 ICU length of stay (days) 11 (5.21) 13 (7.27) 0.543
 ICU mortality 10 (30.3%) 22 (62.9%) 0.007
 Hospital mortality 18 (54.5%) 24 (68.6%) 0.234
 Mortality day 28 15 (45.5%) 21 (60%) 0.23
 Mortality day 90 21 (65.6%) 25 (73.5%) 0.485
Adverse events    0.205
 Hypocalcemia 1 (3%) 6 (17.1%)  
 Metabolic alkalosis 1 (3%) 0 (0%)  
 Citrate accumulation 0 (0%) 0 (0%)  
 Catheter malfunction 1 (3.3%) 1 (2.9%)  
Severe adverse events    0.265
 Treatment-associated life-threatening complication 0 (0%) 0 (0%)  
 Dead of any cause during intervention 2 (6.1%) 5 (14.3%)  
  1. Data presented as n (%). median [25th, 75th quantile]
  2. ICU intensive care unit, CVVHDF continuous veno-venous hemodiafiltration, CVVHD-HCO continuous veno-venous hemodialysis using high cutoff filter